Ziprasidone: Clinical properties and therapeutic promise

Igal Gutnik*, Avraham Weizman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Ziprasidone is a second-generation antipsychotic with combined dopamine and serotonin receptor antagonistic activity. The initial evidence suggests an effective dosage range of 120-160 mg/day. Clinical trials have demonstrated that the drug is an effective antipsychotic in schizophrenia and schizoaffective disorders with some beneficial effect on negative symptoms and on symptoms of depression in schizophrenia. In addition, ziprasidone is efficacious in the manic phase of bipolar disorder. Ziprasidone has relatively few side effects, while its efficacy for florid positive symptoms is at least equivalent to conventional antipsychotics. The main adverse effects are somnolence and nausea. It has a better effect on cognitive deficiencies than conventional antipsychotics. The almost complete lack of weight gain or metabolic side effects makes ziprasidone an attractive second-generation antipsychotic agent.

Original languageEnglish
Pages (from-to)19-27
Number of pages9
JournalFuture Neurology
Issue number1
StatePublished - Jan 2008


  • Bipolar disorder
  • Dopamine
  • Mania
  • Norepinephrine
  • Schizoaffective disorder
  • Schizophrenia
  • Serotonin
  • Ziprasidone


Dive into the research topics of 'Ziprasidone: Clinical properties and therapeutic promise'. Together they form a unique fingerprint.

Cite this